EDEN PRAIRIE, Minn., Jan. 23, 2018 /PRNewswire/ -- MIVI Neuroscience, a company dedicated to developing best-in-class treatment solutions to improve clinical outcomes for stroke patients, today announced that Bob Colloton has joined the company's senior management team as Chief Commercial Officer.
Bob brings 27 years of proven experience in medical device sales and market development and branding expertise, with a deep understanding of the neurovascular market in particular. Most recently he was vice president of Marketing and Sales (USA) for Neuravi Limited and prepared the company for its US market launch of the EmboTrap Revascularization Device. Prior to Neuravi, Bob was vice president Global Sales and Marketing at Revision Optics. He also served as vice president of Global Sales and Marketing at Micrus Endovascular, where he built the sales team and grew the business to become a leading player in neurovascular aneurysm therapy. He also held senior leadership positions in sales and marketing at VNUS Medical, TransVascular, Inc., and Cardiometrics.
"We are excited to bring our unique and broad stroke therapy system, featuring both the R4Q and the DAISe technology, to physicians around the world. At MIVI we are engineering the company for the future, and Bob is a key element of this development. Bob's addition will build on the current organization strengths, demonstrating our investment in building the leadership team for the future," said Jim McCollum, Interim CEO at MIVI. "Bob truly understands this market and the needs of the neurointerventionalists, and he shares our passion for delivering value and striving for excellence. We are thrilled to welcome him to the MIVI family."
"I'm very excited to join MIVI and continue to help improve treatments and thus patient outcomes in the neurovascular market, especially at this exciting time of tremendous growth in acute ischemic stroke treatment," said Bob. "MIVI is a dynamic and innovative company, and I'm inspired by the dedication of the entire team - especially Matt Ogle (our Founder and CTO), Joe Glab (our VP of Sales), Randy LaBounty (our VP of Clinical and Regulatory Affairs) and Scott Olson (our VP of Operations). I look forward to working with the worldwide neurointerventional community to help advance stroke treatment for all patients."
MIVI Neuroscience, Inc. is focused on developing and commercializing superior clinical solutions for neurointerventional procedures. Adoption of endovascular stroke therapy procedures is growing significantly worldwide since compelling data from multiple large-scale randomized trials in 2016 and 2017 confirmed the value to rapidly clear occlusive clot from large cerebral vessels. MIVI's innovative product portfolio provides physicians with unique devices that improve patient outcomes in these procedures by reducing complications, shortening procedure times and expanding treatment to more patients. More information about MIVI can be found on our website, www.mivineuro.com.
Advertisement
Bob brings 27 years of proven experience in medical device sales and market development and branding expertise, with a deep understanding of the neurovascular market in particular. Most recently he was vice president of Marketing and Sales (USA) for Neuravi Limited and prepared the company for its US market launch of the EmboTrap Revascularization Device. Prior to Neuravi, Bob was vice president Global Sales and Marketing at Revision Optics. He also served as vice president of Global Sales and Marketing at Micrus Endovascular, where he built the sales team and grew the business to become a leading player in neurovascular aneurysm therapy. He also held senior leadership positions in sales and marketing at VNUS Medical, TransVascular, Inc., and Cardiometrics.
Advertisement
"We are excited to bring our unique and broad stroke therapy system, featuring both the R4Q and the DAISe technology, to physicians around the world. At MIVI we are engineering the company for the future, and Bob is a key element of this development. Bob's addition will build on the current organization strengths, demonstrating our investment in building the leadership team for the future," said Jim McCollum, Interim CEO at MIVI. "Bob truly understands this market and the needs of the neurointerventionalists, and he shares our passion for delivering value and striving for excellence. We are thrilled to welcome him to the MIVI family."
"I'm very excited to join MIVI and continue to help improve treatments and thus patient outcomes in the neurovascular market, especially at this exciting time of tremendous growth in acute ischemic stroke treatment," said Bob. "MIVI is a dynamic and innovative company, and I'm inspired by the dedication of the entire team - especially Matt Ogle (our Founder and CTO), Joe Glab (our VP of Sales), Randy LaBounty (our VP of Clinical and Regulatory Affairs) and Scott Olson (our VP of Operations). I look forward to working with the worldwide neurointerventional community to help advance stroke treatment for all patients."
MIVI Neuroscience, Inc. is focused on developing and commercializing superior clinical solutions for neurointerventional procedures. Adoption of endovascular stroke therapy procedures is growing significantly worldwide since compelling data from multiple large-scale randomized trials in 2016 and 2017 confirmed the value to rapidly clear occlusive clot from large cerebral vessels. MIVI's innovative product portfolio provides physicians with unique devices that improve patient outcomes in these procedures by reducing complications, shortening procedure times and expanding treatment to more patients. More information about MIVI can be found on our website, www.mivineuro.com.
View original content:http://www.prnewswire.com/news-releases/mivi-neuroscience-selects-bob-colloton-to-lead-worldwide-commercialization-of-innovative-treatment-solution-for-ischemic-stroke-300586275.html
SOURCE MIVI Neuroscience
